

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

(1) POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 18 JULY 2025; (2) EFFECTIVE DATE OF THE CAPITAL REORGANISATION; AND (3) ADJUSTMENTS TO THE SHARE OPTIONS

Reference is made to the circular (“**Circular**”) of New Ray Medicine International Holding Limited (“**Company**”) dated 27 June 2025 and notice (“**Notice**”) of the special general meeting (“**SGM**”) dated 27 June 2025. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in this Circular.

POLL RESULTS OF THE SGM

The Board is pleased to announce that the resolution as set out in the Notice (“**Resolution**”) was duly passed by the Shareholders by way of a poll at the SGM as a special resolution.

As at the date of the SGM, there were a total of 1,671,846,657 Shares in issue, and the Company did not hold any treasury shares (including any treasury shares held or deposited with the Central Clearing and Settlement System). To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, no Shareholder was required to abstain from voting on the resolution proposed at the SGM. As such, there were a total of 1,671,846,657 Shares, representing 100% of the Shares in issue as at the date of the SGM, entitling the Shareholders to attend and vote on the resolution proposed at the SGM. None of the Shareholders was entitled to attend and abstain from voting in favour of the resolution proposed at the SGM according to Rule 13.40 of the Listing Rules. No Shareholder is required under the Listing Rules to abstain from voting. None of the Shareholders have stated their intention in the Circular to vote against the resolution proposed or to abstain from voting at the SGM.

| SPECIAL RESOLUTION | Number of votes and percentage | |
|---|---------------------------------------|----------------|
| | For | Against |
| To approve the Capital Reorganisation and to approve the transactions contemplated thereunder and to authorise any one of the directors of the Company to take all such actions as he/she considers necessary, appropriate, desirable and expedient for the purposes of giving effect to or in connection with the Capital Reorganisation and all transactions contemplated thereunder. | 426,680,480 (100.00%) | 0 (0.00%) |

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the SGM in person, by authorised corporate representative or by proxy.

All Directors attended the SGM in person or via electronic means.

As more than 75% of the votes were cast in favour of the Resolution, the Resolution was duly passed by the Shareholders as a special resolution of the Company.

The Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the SGM.

CAPITAL REORGANISATION

The Board is also pleased to announce that all the conditions precedent to the Capital Reorganisation have been fulfilled and the Capital Reorganisation will become effective on Tuesday, 22 July 2025. Dealings in the New Shares will commence at 9:00 a.m. on Tuesday, 22 July 2025. Please refer to the Circular for details on the trading arrangement, the free exchange of share certificates and matching services for odd lots in connection with the Capital Reorganisation.

Shareholders should note that upon the Capital Reorganisation becoming effective, new share certificates for the New Shares in the colour of yellow will be issued to the Shareholders in order to distinguish them from the existing share certificates for the Existing Shares in the colour of orange.

ADJUSTMENTS TO THE SHARE OPTIONS

As at the date of this announcement, there were 128,200,000 outstanding share options conferring rights to holders of such share options to subscribe for 128,200,000 Existing Shares at the exercise price of HK\$0.287 per Existing Share.

As a result of the Capital Reorganisation, the maximum number of New Shares which may fall to be issued pursuant to the exercise of any Share Options will be adjusted from 128,200,000 Existing Shares to 12,820,000 New Shares and the exercise price will be adjusted to HK\$2.87 per New Share pursuant to the terms of the share option scheme of the Company adopted on 25 October 2013 (“**Share Option Scheme**”).

The above adjustments in relation to the Share Options will take effect simultaneously with the Capital Reorganisation becoming effective on Tuesday, 22 July 2025. Save for the above adjustments, all other terms and conditions of the Share Options remain unchanged.

The auditor of the Company, Moore CPA Limited, has confirmed to the Directors in writing that the adjustments made to the number of Share Options are in accordance with the terms and conditions of the Share Option Scheme, Rule 17.03(13) of the Listing Rules and the supplementary guidance issued by the Stock Exchange on 5 September 2005.

On behalf of the Board

New Ray Medicine International Holding Limited

Wang Qiuqin

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 18 July 2025

As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.